

**Sixth Supplement dated 14 April 2026**  
**to the Base Prospectus for the issue of unsubordinated Notes dated 27 May 2025**



**BNP PARIBAS**

**BNP Paribas Issuance B.V.**

*(incorporated in The Netherlands)*

*(as Issuer)*

**BNP Paribas**

*(incorporated in France)*

*(as Guarantor)*

**BNP Paribas Fortis Funding**

*(incorporated in Luxembourg)*

*(as Issuer)*

**BNP Paribas Fortis SA/NV**

*(incorporated in Belgium)*

*(as Guarantor)*

**Note, Warrant and Certificate Programme**

This sixth supplement (the "**Sixth Supplement**") is supplemental to, and should be read in conjunction with, the base prospectus dated 27 May 2025 (the "**Base Prospectus**"), the first supplement to the Base Prospectus dated 30 June 2025 (the "**First Supplement**"), the second supplement to the Base Prospectus dated 6 August 2025 (the "**Second Supplement**"), the third supplement to the Base Prospectus dated 6 November 2025 (the "**Third Supplement**"), the fourth supplement to the Base Prospectus dated 14 January 2026 (the "**Fourth Supplement**") and the fifth supplement to the Base Prospectus dated 4 March 2026 (the "**Fifth Supplement**") and, together with the First Supplement, the Second Supplement, the Third Supplement and the Fourth Supplement, the "**Previous Supplements**"), in each case, in respect of Notes issued under the Note, Warrant and Certificate Programme (the "**Programme**") of BNP Paribas Issuance B.V. ("**BNPP B.V.**"), BNP Paribas ("**BNPP**") and BNP Paribas Fortis Funding ("**BP2F**").

The Base Prospectus and the Previous Supplements constitute a base prospectus for the purposes of Article 8 of the Prospectus Regulation. "**Prospectus Regulation**" means Regulation (EU) 2017/1129 of 14 June 2017, as amended. The Base Prospectus received approval no. 25-184 on 27 May 2025, the First Supplement received approval no. 25-254 on 30 June 2025, the Second Supplement received approval no. 25-333 on 6 August 2025, the Third Supplement received approval no. 25-427 on 6 November 2025, the Fourth Supplement received approval no. 26-007 on 14 January 2026 and the Fifth Supplement received approval no. 26-044 on 4 March 2026 from the *Autorité des marchés financiers* (the "**AMF**"). Application has been made to the AMF for approval of this Sixth Supplement in its capacity as competent authority under the Prospectus Regulation.

BNPP (in respect of itself and BNPP B.V.), BNPP B.V. (in respect of itself), BP2F (in respect of itself) and BNP Paribas Fortis SA/NV ("**BNPPF**") (in respect of itself and BP2F) accept responsibility for the information contained in this Sixth Supplement, save that BNPP B.V., BP2F and BNPPF accept no responsibility for the BNPP 2025 Universal Registration Document (in English) (as defined below) and the updated disclosure in respect of BNPP. To the best of the knowledge of BNPP, BNPP B.V., BP2F and BNPPF (who have taken all reasonable care to ensure that such is the case), the information contained herein is, subject as provided in the preceding sentence, in accordance with the facts and does not omit anything likely to affect the import of such information.

Unless the context otherwise requires, terms defined in the Base Prospectus, as amended by the Previous Supplements, shall have the same meanings when used in this Sixth Supplement.

To the extent that there is any inconsistency between (i) any statement in this Sixth Supplement and (ii) any statement in, or incorporated by reference in, the Base Prospectus, as amended by the Previous Supplements, the statement referred to in (i) above will prevail.

References in this Sixth Supplement to paragraphs of the Base Prospectus are to the Base Prospectus as amended by the Previous Supplements. References in this Sixth Supplement to page numbers in the Base Prospectus are to the page numbers in the Base Prospectus without taking into account any amendments made in the Previous Supplements.

Copies of this Sixth Supplement will be available on the website of BNPP (<https://rates-globalmarkets.bnpparibas.com/documents/legaldocs/resourceindex.htm>), on the website of BNPPF (<https://www.bnpparibasfortis.be>), on the website of BP2F (<https://www.bp2f.lu>) and on the website of the AMF ([www.amf-france.org](http://www.amf-france.org)).

This Sixth Supplement has been prepared in accordance with Article 23 of the Prospectus Regulation for the purposes of giving information, which amends or is additional to the information already contained in the Base Prospectus, as amended by the Previous Supplements.

This Sixth Supplement has been prepared for the purposes of:

- (A) amending the "Risks" section;
- (B) amending the "Investment Considerations" section;
- (C) amending the "Presentation of Financial Information" section;
- (D) incorporating by reference BNPP's *Document d'Enregistrement Universel au 31 décembre 2025 et rapport financier annuel* (in English) (the **"BNPP 2025 Universal Registration Document (in English)"**);
- (E) amending the "Description of BNPP B.V." section;
- (F) amending the "Description of BNPP" section;
- (G) amending the "Recent Developments" section;
- (H) amending the "General Information" section; and
- (I) amending the Last Page.

The incorporation by reference of the document referred to in (D) above has been made to update the BNPP disclosure. The amendments referred to in (A) to (C), (E), (F) and (H) above have been made to reflect the updated disclosure referred to in (D). The amendments referred to in (A) above have been made to update the risk factors relating to BNP Paribas. The amendments referred to in (G) above have been made to incorporate recent events in relation to the Issuer. The amendments referred to in (E) and (I) above have been made to update the address of BNPP B.V. as of 1 May 2026. The amendments referred to in (D) above have been made to update the cross-reference table relating to BNP Paribas based on Annex 6 of the Commission Delegated Regulation (EU) 2019/980.

**In accordance with Article 23(2) of the Prospectus Regulation, in the case of an offer of Securities to the public, investors who have already agreed to purchase or subscribe for Securities issued under the Programme before this Sixth Supplement is published and which are affected by the amendments made**

**in this Sixth Supplement, have the right, exercisable before the end of the period of three (3) working days beginning with the working day after the date of publication of this Sixth Supplement to withdraw their acceptances. This right to withdraw shall expire by close of business on 20 April 2026. Investors can exercise their right to withdraw their acceptances by contacting the person from whom any such investor has agreed to purchase or subscribe for such Securities before the above deadline.**

## TABLE OF CONTENTS

|                                                                       | Page |
|-----------------------------------------------------------------------|------|
| Amendments to the Risk Section .....                                  | 5    |
| Amendments to the Investment Considerations Section .....             | 6    |
| Amendments to the Presentation of Financial Information Section ..... | 7    |
| Documents Incorporated by Reference .....                             | 8    |
| Amendments to the Description of BNPP B.V. ....                       | 14   |
| Amendments to the Description of BNPP .....                           | 15   |
| Amendments to the Recent Developments Section .....                   | 16   |
| Amendments to the General Information Section .....                   | 20   |
| Amendments to the Last Page .....                                     | 21   |
| Responsibility Statement .....                                        | 22   |

## AMENDMENTS TO THE RISK SECTION

The "**RISKS**" section on pages 29 to 93 of the Base Prospectus (which was amended by virtue of the Previous Supplements) is amended as follows:

the paragraph entitled "**Risk Factors Relating to BNPP**" on page 29 of the Base Prospectus is deleted and replaced with the following:

"Risk Factors relating to BNPP are set out in "Risk Factors" under Chapter 5 on pages 353 to 367 of the BNPP 2025 Universal Registration Document (in English) (as defined below), which are incorporated by reference in this document. See section entitled "*Documents Incorporated by Reference*" of this Base Prospectus.

The following risk factors are identified as the main risk factors specific to BNPP:

1. A substantial increase in new provisions or a shortfall in the level of previously recorded provisions exposed to credit risk and counterparty risk could adversely affect the BNP Paribas Group's results of operations and financial condition.
2. The BNP Paribas Group's risk management policies, procedures and methods may leave it exposed to unidentified or unanticipated risks, which could lead to material losses.
3. The BNP Paribas Group may incur significant losses on its trading and investment activities due to market fluctuations and volatility.
4. The BNP Paribas Group's access to and cost of funding could be adversely affected by a resurgence of financial crises, worsening economic conditions, rating downgrades, increases in sovereign credit spreads or other factors.
5. Adverse economic and financial conditions have in the past and may in the future significantly affect the BNP Paribas Group and the markets in which it operates.
6. Laws and regulations in force, as well as current and future legislative and regulatory developments, may significantly impact the BNP Paribas Group and the financial and economic environment in which it operates.
7. Should the BNP Paribas Group fail to implement its strategic objectives or to achieve its published financial objectives, or should its results not follow stated expected trends, the trading price of its securities could be adversely affected."

## AMENDMENTS TO THE INVESTMENT CONSIDERATIONS SECTION

The "INVESTMENT CONSIDERATIONS" section on pages 94 to 111 of the Base Prospectus is amended as follows:

The fifth paragraph under the sub-heading entitled "*Banking regulations and resolution measures*" on page 97 of the Base Prospectus, which were amended by virtue of the Second Supplement, is amended as follows:

"In June 2025, the Council and the European Parliament announced that they had reached a political agreement on ~~the remaining part of~~ the CMDI package proposed by the European Commission in April 2023. ~~The Council and the European Parliament must now finalize the legal text and formally adopt this new framework before entering into force (the date of which is unknown).~~ On 5 March 2026, the Council agreed on the CMDI proposal in first reading, and on 26 March 2026, the European Parliament also voted in favour of this new framework. This will be followed by the formal adoption by the Council before it can enter into force (which is not expected before the second quarter of 2028).".

## AMENDMENTS TO THE PRESENTATION OF FINANCIAL INFORMATION SECTION

The second paragraph under the heading "**PRESENTATION OF FINANCIAL INFORMATION**" on page 116 of the Base Prospectus is amended as follows:

"The audited consolidated financial statements of BNPP for the years ended 31 December ~~2023~~2024 and 31 December ~~2024~~2025 have been prepared in accordance with International Financial Reporting Standards ("**IFRS**") as adopted by the European Union. IFRS differs in certain significant respects from generally accepted accounting principles in the United States ("**U.S. GAAP**"). The Group has made no attempt to quantify the impact of those differences. In making an investment decision, investors must rely upon their own examination of the Group, the terms of an offering and the financial information. Potential investors should consult their own professional advisors for an understanding of the differences between IFRS and U.S. GAAP, and how those differences might affect the information herein. The Group's fiscal year ends on 31 December and references in the BNPP ~~2023~~2024 Universal Registration Document (in English) and the BNPP ~~2024~~2025 Universal Registration Document (in English) and any amendment to the BNPP ~~2024~~2025 Universal Registration Document (in English) (in each case, as defined in "*Documents Incorporated by Reference*" below and incorporated by reference herein) to any specific fiscal year are to the 12-month period ended 31 December of such year."

## DOCUMENTS INCORPORATED BY REFERENCE

On 19 March 2026, BNPP filed with the AMF the *Document d'Enregistrement Universel 2025 et rapport financier annuel* in English, including the English version of the audited financial information of BNPP as at 31 December 2025 and the audit report thereon, of which the pages appearing in the cross-reference table below are incorporated in, and forms part of, the Base Prospectus by virtue of this Sixth Supplement.

The "**DOCUMENTS INCORPORATED BY REFERENCE**" section on pages 117 to 138 of the Base Prospectus (which was amended by virtue of the Previous Supplements) is amended as follows:

- (a) paragraphs (n), (p), (q), (r), (s) and (t) (which were in the Base Prospectus or added to the Base Prospectus by virtue of the Previous Supplements) are deleted;
- (b) the paragraph (o) is renumbered (n) and the "; and" is added at the end of paragraph;
- (c) the following paragraph (o) is added under paragraph (n):

"(o) BNPP's *Document d'Enregistrement Universel au 31 décembre 2025 et rapport financier annuel* in English, including the consolidated financial statements for the year ended 31 December 2025 and the statutory auditors' report thereon, with filing number D.26-0113 (the "**BNPP 2025 Universal Registration Document (in English)**"),"
- (d) in the last paragraph on page 138 of the Base Prospectus, the second sentence is deleted and replaced as follows:

"Each of the documents incorporated by reference in (c) to (o) above will only be made available by the relevant Issuer or the relevant Guarantor to which such document relates."; and
- (e) the table entitled "**BNP PARIBAS**" on pages 128 to 132 of the Base Prospectus (which was amended by virtue of the Previous Supplements) is deleted and replaced with the following table:



| BNP PARIBAS                                                                                                                              |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Information incorporated by reference                                                                                                    | Page Reference                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                         |
|                                                                                                                                          | BNPP 2024 Universal Registration Document (in English) -<br><a href="https://invest.bnpparibas/en/document/universal-registration-document-annual-financial-report-2024-pdf">https://invest.bnpparibas/en/document/universal-registration-document-annual-financial-report-2024-pdf</a> | BNPP 2025 Universal Registration Document (in English) -<br><a href="https://invest.bnpparibas/en/document/universal-registration-document-annual-financial-report-2025-pdf">https://invest.bnpparibas/en/document/universal-registration-document-annual-financial-report-2025-pdf</a> |
| <i>Annex 6 of the Commission Delegated Regulation (EU) 2019/980</i>                                                                      |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
| <b>1. Persons responsible, third-party information, experts' reports and competent authority approval</b>                                |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
| <i>1.1 Persons responsible for the information</i>                                                                                       |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
| <i>1.2 Declaration by the persons responsible for the registration document</i>                                                          |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
| <i>1.3 Statement or report by an expert or at the Issuer's request</i>                                                                   |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
| <i>1.4 Information sourced from a third party</i>                                                                                        |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
| <i>1.5 Statement regarding the competent authority approval</i>                                                                          |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
| <b>2. Statutory auditors</b>                                                                                                             |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
| <i>2.1 Names and addresses of the Issuer's auditors</i>                                                                                  | 938                                                                                                                                                                                                                                                                                     | 923                                                                                                                                                                                                                                                                                     |
| <i>2.2 Resignation, removal or no re-appointment of auditors</i>                                                                         |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
| <b>3. Risk factors</b>                                                                                                                   |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
| <i>3.1 Material risks specific to the Issuer and that may affect the Issuer's ability to fulfil its obligations under the securities</i> |                                                                                                                                                                                                                                                                                         | 353-367                                                                                                                                                                                                                                                                                 |
| <b>4. Information about the Issuer</b>                                                                                                   |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |

|                                                                                                                                                   |  |                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------------------------|
| 4.1. History and development of the Issuer.                                                                                                       |  |                                                      |
| 4.1.1 Legal and commercial name of the Issuer.                                                                                                    |  | 4                                                    |
| 4.1.2 Place of registration of the Issuer, registration number and legal entity identifier ('LEI').                                               |  | 896                                                  |
| 4.1.3 Date of incorporation and length of life of the Issuer, except where the period is indefinite.                                              |  | 915                                                  |
| 4.1.4 Domicile, legal form, legislation, country of incorporation, address, telephone number and website of the Issuer                            |  | 896                                                  |
| 4.1.5 Details of any recent events particular to the Issuer and which are to a material extent relevant to an evaluation of the issuer's solvency |  | 177                                                  |
| 4.1.6 Credit ratings assigned to an Issuer at the request or with the cooperation of the Issuer in the rating process.                            |  | 6                                                    |
| 4.1.7 Information on the material changes in the Issuer's borrowing and funding structure since the last year financial year.                     |  | 897                                                  |
| 4.1.8 Description of the expected financing of the Issuer's activities.                                                                           |  | 563-582                                              |
| <b>5. Business overview</b>                                                                                                                       |  |                                                      |
| 5.1 Principal activities                                                                                                                          |  |                                                      |
| 5.1.1 Issuer's principal activities                                                                                                               |  | 6; 9-23; 27; 152-196; 242-247; 377-380; 454; 898-914 |
| 5.2 Basis for any statements made by the issuer regarding its competitive position                                                                |  | 9-22; 152-162                                        |
| <b>6. Organisational structure</b>                                                                                                                |  |                                                      |
| 6.1 Brief description of the group and the Issuer's position within the group.                                                                    |  | 4-8; 707                                             |
| 6.2 Issuer's dependence upon other entities.                                                                                                      |  | 683-687                                              |
| <b>7. Trend Information</b>                                                                                                                       |  |                                                      |

|            |                                                                                                                                                                                                                                                                                                                                 |  |                             |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------|
| 7.1        | <i>(a) Description of any material adverse change in the prospects of the issuer since the date of its last published audited financial statements;<br/>(b) any significant change in the financial performance of the group since the end of the last financial period for which financial information has been published.</i> |  | 178-180; 897                |
| 7.2        | <i>Trends, uncertainties, demands, commitments or events</i>                                                                                                                                                                                                                                                                    |  | 178-180; 897                |
| <b>8.</b>  | <b>Profit forecasts or estimates</b>                                                                                                                                                                                                                                                                                            |  |                             |
| 8.1        | <i>Profit forecast or estimate</i>                                                                                                                                                                                                                                                                                              |  |                             |
| 8.2        | <i>New profit forecast or estimate</i>                                                                                                                                                                                                                                                                                          |  |                             |
| 8.3        | <i>Statement on the profit forecast or estimate</i>                                                                                                                                                                                                                                                                             |  |                             |
| <b>9.</b>  | <b>Administrative, management, and supervisory bodies</b>                                                                                                                                                                                                                                                                       |  |                             |
| 9.1        | <i>Names, business addresses and functions of members of the administrative, management or supervisory bodies</i>                                                                                                                                                                                                               |  | 37-53; 86-92; 102; 124; 131 |
| 9.2        | <i>Administrative, management, and supervisory bodies' conflicts of interests</i>                                                                                                                                                                                                                                               |  | 58-63; 80-81; 88-89         |
| <b>10.</b> | <b>Major shareholders</b>                                                                                                                                                                                                                                                                                                       |  |                             |

|            |                                                                                                                        |                                                                                                |                                                                                                        |
|------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| 10.1       | <i>Control of the Issuer</i>                                                                                           |                                                                                                | 23-24                                                                                                  |
| 10.2       | <i>Description of any arrangements</i>                                                                                 |                                                                                                | 24                                                                                                     |
| <b>11.</b> | <b>Financial information concerning the Issuer's assets and liabilities, financial position and profits and losses</b> |                                                                                                |                                                                                                        |
| 11.1       | <i>Historical financial information</i>                                                                                |                                                                                                |                                                                                                        |
| 11.1.1     | <i>Audited historical information</i>                                                                                  | 187-322; 394-404; 409-410; 459-478; 485; 491; 519-520; 528-534; 537; 544-545; 559-562; 635-672 | 197-335; 409-419; 424-426; 483-502; 512; 518-519; 548-549; 557-563; 566-567; 575-576; 593-596; 653-688 |
| 11.1.2     | <i>Change of accounting reference date</i>                                                                             |                                                                                                |                                                                                                        |
| 11.1.3     | <i>Accounting Standards</i>                                                                                            | 196-197; 638-645                                                                               | 206-207; 656-663                                                                                       |
| 11.1.4     | <i>Change of accounting framework</i>                                                                                  |                                                                                                |                                                                                                        |
| 11.1.5     | <i>National accounting standards</i>                                                                                   | 635-672                                                                                        | 653-688                                                                                                |
| 11.1.6     | <i>Consolidated financial statements</i>                                                                               | 190-322                                                                                        | 200-335                                                                                                |
| 11.1.7     | <i>Age of financial information</i>                                                                                    | 192                                                                                            | 202                                                                                                    |
| 11.2       | <i>Interim and other financial information</i>                                                                         |                                                                                                |                                                                                                        |
| 11.2.1     | <i>Quarterly or half-yearly financial information</i>                                                                  |                                                                                                |                                                                                                        |
| 11.3       | <i>Auditing of historical annual financial information</i>                                                             |                                                                                                |                                                                                                        |
| 11.3.1     | <i>Historical annual financial information independently audited</i>                                                   | 323-329; 675-680                                                                               | 336-342; 692-697                                                                                       |
| 11.3.1 a   | <i>Refusal, qualifications, modifications of opinion, disclaimers or emphasis of matter by the auditors</i>            |                                                                                                |                                                                                                        |
| 11.3.2     | <i>Other information audited</i>                                                                                       | 936-937                                                                                        | 921-922                                                                                                |
| 11.3.3     | <i>Source of not audited information</i>                                                                               |                                                                                                |                                                                                                        |
| 11.4       | <i>Legal and arbitration proceedings</i>                                                                               |                                                                                                |                                                                                                        |
| 11.4.1     | <i>Information on any governmental, legal or arbitration proceedings</i>                                               | 294-295                                                                                        | 305-306                                                                                                |
| 11.5       | <i>Significant change in the issuer's financial position</i>                                                           |                                                                                                |                                                                                                        |
| 11.5.1     | <i>Description of any significant change in the financial position of the group</i>                                    |                                                                                                | 897                                                                                                    |
| <b>12.</b> | <b>Additional information</b>                                                                                          |                                                                                                |                                                                                                        |
| 12.1       | <i>Share capital</i>                                                                                                   |                                                                                                | 23; 301-302; 680; 915                                                                                  |
| 12.2       | <i>Memorandum of Articles of Association</i>                                                                           |                                                                                                | 915-920                                                                                                |

|                                               |  |     |
|-----------------------------------------------|--|-----|
| <b>13. Material contracts</b>                 |  |     |
| <i>13.1 Summary of each material contract</i> |  | 896 |
| <b>14. Documents available</b>                |  |     |
| <i>14.1 Availability of the documents</i>     |  | 896 |

## AMENDMENTS TO THE DESCRIPTION OF BNPP B.V.

The "**DESCRIPTION OF BNPP B.V.**" section on pages 1344 to 1347 of the Base Prospectus is amended as follows:

- (a) The subparagraph (b) under the heading "**1. Name, registered office and date of incorporation**" on page 1344 of the Base Prospectus will be amended as follows:

"(b) **Until 30 April 2026 (included):**

BNPP B.V. is a limited liability company under Dutch law ("*besloten vennootschap met beperkte aansprakelijkheid*"), having its registered office at Herengracht 595, 1017 CE Amsterdam, The Netherlands. BNPP B.V. is incorporated in The Netherlands and registered with the Commercial Register in The Netherlands under number 33215278 (telephone number: + 31 (0)88 738 0000). The legal entity identifier (LEI) of BNPP B.V. is 7245009UXRIGIRYOB48.;

**From 1 May 2026 (included):**

BNPP B.V. is a limited liability company under Dutch law ("*besloten vennootschap met beperkte aansprakelijkheid*"), having its registered office at Parnassusweg 789, 1082 LZ Amsterdam, The Netherlands. BNPP B.V. is incorporated in The Netherlands and registered with the Commercial Register in The Netherlands under number 33215278 (telephone number: + 31 (0)88 738 0000). The legal entity identifier (LEI) of BNPP B.V. is 7245009UXRIGIRYOB48.";

- (b) The paragraph under the heading "**3. Trend Information**" on page 1345 of the Base Prospectus is amended as follows:

"Due to BNPP B.V.'s dependence upon BNPP, its trend information is the same as that for BNPP set out on page ~~911~~897 of the BNPP ~~2024~~2025 Universal Registration Document (in English).".

## **AMENDMENTS TO THE DESCRIPTION OF BNPP**

The paragraph under the heading "**Description of BNPP**" on page 1348 of the Base Prospectus is amended as follows:

"A description of BNPP can be found on pages 4 to ~~78~~ of the BNPP ~~2024~~2025 Universal Registration Document (in English) which is incorporated by reference herein."

## AMENDMENTS TO THE RECENT DEVELOPMENTS SECTION

The "RECENT DEVELOPMENTS" section on pages 1489 to 1524 of the Base Prospectus, which has been amended by virtue of the Previous Supplements, is completed with the following press releases:

### "RESTATEMENT OF NEW 2025 QUARTERLY SERIES IN THE 2026 FORMAT

Paris, 16 March 2026

**This restatement has no impact on the Group's published 2025 results and changes only the analytical breakdown of business lines and divisions.**

In order to present a consistent reference with the presentation of the financial statements and the results applied from 1 January 2026, the quarterly series for the 2025 financial year include the main effects described below:

- **Reorganisation of GCM (Global Capital Markets) within CIB**  
*Impact: nil at CIB level and intra-division transfer of P&L and RWAs*  
CIB Global Capital Markets reorganised both Securitization & Corporate Bonds activities in AMERICAS and APAC to fully align CIB organization at worldwide level. The RWAs of the relevant activities (~€12bn) are therefore moved from Global Markets (GM) to Global Banking (GB).  
The revenue sharing between GB and GM has evolved to align across the 3 regions, though with a limited net impact on the total revenues of both businesses (~€0.1bn).  
This regional alignment of CIB organisation aims at reinforcing worldwide governance. It also contributes to reinforcing GB and GM joint efforts to further develop Originate & Distribute model.
- **Evolution of the sharing agreement between Wealth Management (WM) and CPBS**  
*Impact: €17M at revenue level*  
The revenue sharing agreement between WM and the internal distribution networks (largely the Commercial Banks), aiming at recognizing to the networks their contribution to the value created for WM, has been updated to better reflect the recognition of the upstreaming role of the networks.
- **Transfer of 50% of Kantox from New Digital Businesses (NDB) to GM**  
*Impact: €11M at revenue level*  
Kantox's contribution was previously 50/50 shared between GM and NDB.  
In order to enable GM to fully benefit from the integration of this activity, the entire contribution from Kantox is now transferred to GM.
- **Evolution of the main components of IPS and central costs allocation following the integration of AXA IM into the Asset Management (AM)**  
*Impact: €8M at costs level*  
Given the recent acquisition of AXA Investment Managers (AXA IM) by the BNP Paribas Group, the AM business line is now composed of the former BNP Paribas Asset Management, AXA IM and Real Estate Investment Management.  
The rest of Real Estate and IPS Investments, previously presented with Asset Management, will now be aggregated with Wealth Management.  
As a result of the full integration of AXA IM in the AM business line, a share of the central costs previously allocated to the other business lines (CIB, CPBS and other IPS business lines) is now allocated to AM business line.

The following non-audited appendices detail the 2025 quarterly results in line with these developments.



New quarterly series in excel format are available on the following website: <https://invest.bnpparibas.com>.

## **Calendar**

- 15 April 2026: Start of the quiet period
- 30 April 2026: Publication of 1Q26 results
- 12 May 2026: Annual General Meeting
- 18 May 2026: Detachment date of balance dividend on 2025 earnings (subject to the approval of the Annual General Meeting of 12 May 2026)
- 20 May 2026: Payment date of balance dividend on 2025 earnings (subject to the approval of the Annual General Meeting of 12 May 2026)
- 1 June 2026: Deep Dive Commercial & Personal Banking in Belgium
- 23 July 2026: Publication of 2Q26 & 1H26 results

## **Investor relations contact**

Bénédicte Thibord - [benedicte.thibord@bnpparibas.com](mailto:benedicte.thibord@bnpparibas.com)

## **Equity**

Meriem Afilal Costard - [meriem.afilalcostard@bnpparibas.com](mailto:meriem.afilalcostard@bnpparibas.com)

Raphaëlle Bouvier-Flory - [raphaelle.bouvierflory@bnpparibas.com](mailto:raphaelle.bouvierflory@bnpparibas.com)

Lisa Bugat - [lisa.bugat@bnpparibas.com](mailto:lisa.bugat@bnpparibas.com)

Tania Mansour - [tania.mansour@bnpparibas.com](mailto:tania.mansour@bnpparibas.com)

Olivier Parenty - [olivier.parenty@bnpparibas.com](mailto:olivier.parenty@bnpparibas.com)

Guillaume Tiberghien - [guillaume.tiberghien@uk.bnpparibas.com](mailto:guillaume.tiberghien@uk.bnpparibas.com)

## **Debt & Rating agencies**

Tania Mansour - [tania.mansour@bnpparibas.com](mailto:tania.mansour@bnpparibas.com)

Olivier Parenty - [olivier.parenty@bnpparibas.com](mailto:olivier.parenty@bnpparibas.com)

## **Retail & ESG**

Lisa Bugat - [lisa.bugat@bnpparibas.com](mailto:lisa.bugat@bnpparibas.com)

Antoine Labarsouque - [antoine.labarsouque@bnpparibas.com](mailto:antoine.labarsouque@bnpparibas.com)

E-mail : [investor.relations@bnpparibas.com](mailto:investor.relations@bnpparibas.com)

## APPENDIX 1: 2025 RESTATED GROUP PROFIT & LOSS, UNCHANGED COMPARED TO 2025 PUBLISHED GROUP PROFIT & LOSS

| €m                                          | Effects of the 2025 restated |                                                                  |                                                   |                                                                                                             | 2025<br>Restated |
|---------------------------------------------|------------------------------|------------------------------------------------------------------|---------------------------------------------------|-------------------------------------------------------------------------------------------------------------|------------------|
|                                             | 2025<br>Published            | Evolution of<br>the sharing<br>agreement<br>between WM<br>& CPBS | Transfer of<br>50% of<br>Kantox from<br>NDB to GM | Central<br>costs<br>allocation<br>following the<br>integration of<br>AXA IM into<br>the Asset<br>Management |                  |
| <b>Revenues</b>                             | <b>51,223</b>                |                                                                  |                                                   |                                                                                                             | <b>51,223</b>    |
| Operating Expenses and Dep.                 | -31,374                      |                                                                  |                                                   |                                                                                                             | -31,374          |
| <b>Gross Operating Income</b>               | <b>19,849</b>                |                                                                  |                                                   |                                                                                                             | <b>19,849</b>    |
| Cost of Risk and others                     | -3,553                       |                                                                  |                                                   |                                                                                                             | -3,553           |
| <b>Operating Income</b>                     | <b>16,296</b>                |                                                                  |                                                   |                                                                                                             | <b>16,296</b>    |
| Share of Earnings of Equity-Method Entities | 777                          |                                                                  |                                                   |                                                                                                             | 777              |
| Other Non Operating Items                   | -8                           |                                                                  |                                                   |                                                                                                             | -8               |
| <b>Pre-Tax Income</b>                       | <b>17,065</b>                |                                                                  |                                                   |                                                                                                             | <b>17,065</b>    |

## APPENDIX 2: EFFECTS OF THE RESTATEMENT ON OPERATING DIVISIONS

Effects of the 2025 restated

| €m                                                                                                                                                                   | 2025<br>Published | Evolution of<br>the sharing<br>agreement<br>between WM<br>& CPBS | Transfer of<br>50% of<br>Kantox from<br>NDB to GM | Central<br>costs<br>allocation<br>following the<br>integration of<br>AXA IM into<br>the Asset<br>Management | 2025<br>Restated |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------------------------------------------------|---------------------------------------------------|-------------------------------------------------------------------------------------------------------------|------------------|
| <b>Commercial, Personal Banking &amp; Services (including 2/3 of Private Banking)</b>                                                                                |                   |                                                                  |                                                   |                                                                                                             |                  |
| <b>Revenues</b>                                                                                                                                                      | <b>26,717</b>     | <b>17</b>                                                        | <b>-11</b>                                        |                                                                                                             | <b>26,723</b>    |
| Operating Expenses and Dep.                                                                                                                                          | -16,053           |                                                                  | 17                                                | 5                                                                                                           | -16,032          |
| <b>Gross Operating Income</b>                                                                                                                                        | <b>10,663</b>     | <b>17</b>                                                        | <b>6</b>                                          | <b>5</b>                                                                                                    | <b>10,691</b>    |
| Cost of Risk and others                                                                                                                                              | -3,059            |                                                                  |                                                   |                                                                                                             | -3,059           |
| <b>Operating Income</b>                                                                                                                                              | <b>7,604</b>      | <b>17</b>                                                        | <b>6</b>                                          | <b>5</b>                                                                                                    | <b>7,631</b>     |
| Share of Earnings of Equity-Method Entities                                                                                                                          | 423               |                                                                  |                                                   |                                                                                                             | 423              |
| Other Non Operating Items                                                                                                                                            | -222              |                                                                  |                                                   |                                                                                                             | -222             |
| <b>Pre-Tax Income</b>                                                                                                                                                | <b>7,805</b>      | <b>17</b>                                                        | <b>6</b>                                          | <b>5</b>                                                                                                    | <b>7,832</b>     |
| <b>Investment &amp; Protection Services</b>                                                                                                                          |                   |                                                                  |                                                   |                                                                                                             |                  |
| <b>Revenues</b>                                                                                                                                                      | <b>6,929</b>      | <b>-17</b>                                                       |                                                   |                                                                                                             | <b>6,912</b>     |
| Operating Expenses and Dep.                                                                                                                                          | -4,158            |                                                                  |                                                   | -8                                                                                                          | -4,166           |
| <b>Gross Operating Income</b>                                                                                                                                        | <b>2,771</b>      | <b>-17</b>                                                       |                                                   | <b>-8</b>                                                                                                   | <b>2,745</b>     |
| Cost of Risk and others                                                                                                                                              | -10               |                                                                  |                                                   |                                                                                                             | -10              |
| <b>Operating Income</b>                                                                                                                                              | <b>2,761</b>      | <b>-17</b>                                                       |                                                   | <b>-8</b>                                                                                                   | <b>2,736</b>     |
| Share of Earnings of Equity-Method Entities                                                                                                                          | 186               |                                                                  |                                                   |                                                                                                             | 186              |
| Other Non Operating Items                                                                                                                                            | 142               |                                                                  |                                                   |                                                                                                             | 142              |
| <b>Pre-Tax Income</b>                                                                                                                                                | <b>3,089</b>      | <b>-17</b>                                                       |                                                   | <b>-8</b>                                                                                                   | <b>3,064</b>     |
| <b>Corporate and Institutional Banking</b>                                                                                                                           |                   |                                                                  |                                                   |                                                                                                             |                  |
| <b>Revenues</b>                                                                                                                                                      | <b>18,997</b>     |                                                                  | <b>11</b>                                         |                                                                                                             | <b>19,008</b>    |
| Operating Expenses and Dep.                                                                                                                                          | -11,061           |                                                                  | -17                                               | 3                                                                                                           | -11,074          |
| <b>Gross Operating Income</b>                                                                                                                                        | <b>7,936</b>      |                                                                  | <b>-6</b>                                         | <b>3</b>                                                                                                    | <b>7,933</b>     |
| Cost of Risk and others                                                                                                                                              | -452              |                                                                  |                                                   |                                                                                                             | -452             |
| <b>Operating Income</b>                                                                                                                                              | <b>7,484</b>      |                                                                  | <b>-6</b>                                         | <b>3</b>                                                                                                    | <b>7,481</b>     |
| Share of Earnings of Equity-Method Entities                                                                                                                          | 20                |                                                                  |                                                   |                                                                                                             | 20               |
| Other Non Operating Items                                                                                                                                            | 3                 |                                                                  |                                                   |                                                                                                             | 3                |
| <b>Pre-Tax Income</b>                                                                                                                                                | <b>7,506</b>      |                                                                  | <b>-6</b>                                         | <b>3</b>                                                                                                    | <b>7,503</b>     |
| <b>Corporate Center incl. restatement related to insurance activities of the volatility (IFRS 9 ) and attributable costs (internal distribution) and PF non core</b> |                   |                                                                  |                                                   |                                                                                                             |                  |
| <b>Revenues</b>                                                                                                                                                      | <b>-1,420</b>     |                                                                  |                                                   |                                                                                                             | <b>-1,420</b>    |
| Operating Expenses and Dep.                                                                                                                                          | -101              |                                                                  |                                                   |                                                                                                             | -101             |
| <b>Gross Operating Income</b>                                                                                                                                        | <b>-1,521</b>     |                                                                  |                                                   |                                                                                                             | <b>-1,521</b>    |
| Cost of Risk and others                                                                                                                                              | -32               |                                                                  |                                                   |                                                                                                             | -32              |
| <b>Operating Income</b>                                                                                                                                              | <b>-1,553</b>     |                                                                  |                                                   |                                                                                                             | <b>-1,553</b>    |
| Share of Earnings of Equity-Method Entities                                                                                                                          | 149               |                                                                  |                                                   |                                                                                                             | 149              |
| Other Non Operating Items                                                                                                                                            | 69                |                                                                  |                                                   |                                                                                                             | 69               |
| <b>Pre-Tax Income</b>                                                                                                                                                | <b>-1,335</b>     |                                                                  |                                                   |                                                                                                             | <b>-1,335</b>    |

"

## AMENDMENTS TO THE GENERAL INFORMATION SECTION

The "**GENERAL INFORMATION**" section on pages 1525 to 1538 of the Base Prospectus, which has been amended by virtue of the Previous Supplements, is amended as follows:

- (a) the first paragraph under the heading "**5. Material Adverse Change**" on page 1525 of the Base Prospectus (which was amended by virtue of the Previous Supplements) is amended as follows:

~~"Except as disclosed in this Base Prospectus, t~~There has been no material adverse change in the prospects of BNPP or the Group since 31 December ~~2024~~2025 (being the end of the last financial period for which audited financial statements have been published).";

- (b) the first paragraph under the heading "**6. Legal and Arbitration Proceedings**" on page 1526 of the Base Prospectus (which was amended by virtue of the Previous Supplements) is amended as follows:

"Save as disclosed on pages ~~294~~305 and ~~295~~306 of the BNPP ~~2024~~2025 Universal Registration Document (in English), ~~pages 91 to 93 of the First Amendment to the BNPP 2024 Universal Registration Document, pages 325 to 327 of the Second Amendment to the BNPP 2024 Universal Registration Document, pages 94 to 96 of the Third Amendment to the BNPP 2024 Universal Registration Document and pages 134 and 135 of the 2025 BNPP Unaudited Financial Statements,~~ there have been no governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which BNPP is aware), during the period covering the twelve (12) months prior to the date of this Base Prospectus which may have, or have had in the recent past, significant effects on BNPP's and/or the Group's financial position or profitability.";

- (c) the first paragraph under the heading "**10. Board of Directors**" on page 1527 of the Base Prospectus (which was amended by virtue of the Second Supplement) is amended as follows:

"The members of the Board of Directors of BNPP are displayed on pages ~~353~~9 to ~~505~~1 of the BNPP ~~2024~~2025 Universal Registration Document (in English), ~~and pages 318 to 324 of the Second Amendment to the BNPP 2024 Universal Registration Document (in English)~~ relating to BNPP, which ~~are~~is incorporated by reference herein.";

- (d) the first paragraph under the heading "**11. Conflicts of Interests**" on page 1527 of the Base Prospectus (which was amended by virtue of the Second Supplement) is amended as follows:

"To the ~~best of the Board of Directors'~~ knowledge ~~of the Bank~~, the duties owed by the members of the Board of Directors of ~~the Bank~~BNPP do not give rise to any potential conflicts of interest with such members' private interests or other duties. ~~In any case, the Suitability policy requires directors to report any situation likely to constitute a conflict of interest to the Chairman. Measures aimed at avoiding and managing conflicts of interest are established in the Internal Rules of the Board of Directors of BNPP.~~"; and

- (e) the heading "**19. Declaration concerning the unaudited results of BNP Paribas for the periods ending 31 December 2025**" and the paragraphs thereunder (which were added to the Base Prospectus by virtue of the Fifth Supplement) are deleted.

## AMENDMENTS TO THE LAST PAGE

The items under the heading "**Issuers**" on page 1540 of the Base Prospectus will be deleted and replaced with the following:

### ISSUERS

Until 30 April 2026 (included):

**BNP Paribas Issuance B.V.**  
Herengracht 595  
1017 CE AMSTERDAM  
The Netherlands

**BNP Paribas Fortis Funding**  
19, rue Eugène Ruppert  
L-2453 Luxembourg  
Grand Duchy of Luxembourg

From 1 May 2026 (included):

**BNP Paribas Issuance B.V.**  
Parnassusweg 789  
1082 LZ AMSTERDAM  
The Netherlands

**BNP Paribas Fortis Funding**  
19, rue Eugène Ruppert  
L-2453 Luxembourg  
Grand Duchy of Luxembourg

## **RESPONSIBILITY STATEMENT**

I hereby certify on behalf of BNPP, BNPP B.V., BP2F and BNPPF that, to the best of my knowledge, the information contained in this Sixth Supplement is in accordance with the facts and makes no omission likely to affect its import.

BNP Paribas  
16 boulevard des Italiens  
75009 Paris  
France

Represented by Lars MACHENIL  
in his capacity as Chief Financial Officer

Dated 14 April 2026



*Autorité des marchés financiers*

This Sixth Supplement has been approved on 14 April 2026 by the AMF, in its capacity as competent authority under Regulation (EU) 2017/1129.

The AMF has approved this Sixth Supplement after having verified that the information it contains is complete, coherent and comprehensible within the meaning of Regulation (EU) 2017/1129. The approval does not imply the verification of the accuracy of this information by the AMF.

This approval is not a favourable opinion on the Issuers (or the Guarantors) or on the quality of the Securities described in this Sixth Supplement. Investors should make their own assessment of the opportunity to invest in such Securities.

This Sixth Supplement obtained the following approval number: n°26-082.